TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29223585

Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice drink (BR; 55 mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-concentrated beetroot juice drink (BL; 456 mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solid beetroot flapjack (BF; 60 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soluble beetroot crystals (BC; ∼1.40 mmol NO3‐)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink (CON; 70 mL deionised water)
Number of subjects: 10
Study: 27341973

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional Dry Dressings (CDD)
Number of subjects: 33
Study: 24566875

Group type: EXPERIMENTAL
Intervention: Pressing a training device ( +  condition)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Keeping the hand quiet ( ‐ condition)
Number of subjects: 8
Study: 23031570

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (1 MHz & 1.5 W/cm2) plus exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo ultrasound plus exercise
Number of subjects: 50
Study: 21211430

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion at 21 o'clock
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion at 9 o'clock
Number of subjects: 111
Study: 17286243

Group type: EXPERIMENTAL
Intervention: Montelukast (0 - 0 - 10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16119601

Group type: EXPERIMENTAL
Intervention: Sevoflurane end‐tidal 2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane end‐tidal 1.1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 6 mg kg(‐1) h(‐1) in oxygen 33% and air
Number of subjects: 60
Study: 11833666

Group type: EXPERIMENTAL
Intervention: Selective rationing option (test B)
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Lottery selection for test B beneficiaries
Number of subjects: 1184

Group type: COMPARATOR
Intervention: First-come-first-served selection for test B beneficiaries
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Medical associations selection for test B beneficiaries
Number of subjects: 1184
Study: 10427382

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural analgesia (EP)
Number of subjects: 80
Study: 7646664

Group type: EXPERIMENTAL
Intervention: Physician reminder letter and telephone contact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 2179283

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 50 mg once daily for 4 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 50 mg daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 696981

Group type: EXPERIMENTAL
Intervention: Diazepam (Valium) 0.3 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 30
Study: 29254116

Group type: EXPERIMENTAL
Intervention: Resistance expiratory muscle strength training (EMST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group (sham EMST device with no loading)
Number of subjects: 42
Study: 25798748

Group type: EXPERIMENTAL
Intervention: Continuous urinary catheterization (CC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intermittent catheters (IC)
Number of subjects: 123
Study: 23510189

Group type: EXPERIMENTAL
Intervention: Informed group (n = 172)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Uninformed group (n = 160)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Overall agreement
Number of subjects: 332
Study: 21145839

Group type: EXPERIMENTAL
Intervention: BI201335 20 mg once-daily for 14 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 48 mg once-daily for 14 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 120 mg once-daily for 14 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 240 mg once-daily for 14 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 48 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 120 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BI201335 240 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19994683

Group type: EXPERIMENTAL
Intervention: Five-needle-in-nape acupuncture (FNN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture (RA)
Number of subjects: 60
Study: 16770028

Group type: EXPERIMENTAL
Intervention: Topical Mitomycin C (0.01%)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 28
Study: 15511682

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) monotherapy initiated at 2mg/kg, increased to maintenance dosage of 8.0 mg/kg (mean, 7.97 +/- 0.55 mg/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) monotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) with carbamazepine (CBZ) added in 12 patients with uncontrolled seizures
Number of subjects: 72
Study: 11354781

Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 95

Group type: COMPARATOR
Intervention: ACE ID or II genotype
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Gross proteinuria
Number of subjects: 95
Study: 9172045

Group type: EXPERIMENTAL
Intervention: CHG‐5 protocol (initial scrub of 5 min and consecutive scrubs of 3.5 min with chlorhexidine gluconate 4%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CHG‐3 protocol (initial scrub of 3 min and consecutive scrubs of 2.5 min with chlorhexidine gluconate 4%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PI‐3 protocol (initial scrub of 3 min and consecutive scrubs of 2.5 min with povidone iodine 5% and triclosan 1%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: IPA protocol (initial scrub of 2 min with chlorhexidine gluconate 4% followed by isopropanol 70% and chlorhexidine gluconate 0.5%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EA protocol (initial scrub of 2 min with chlorhexidine gluconate 4% followed by ethanol 70% and chlorhexidine gluconate 0.5%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alcohol-based antiseptics (IPA and EA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Detergent-based antiseptics (CHG‐5, CHG‐3, PI‐3)
Number of subjects: 23
Study: 8252111

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogens, 0.625 mg daily, with cyclical oral dl-norgestrel, 0.15 mg daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-oestradiol, 0.05 mg daily, with cyclical transdermal norethisterone acetate, 0.25 mg daily
Number of subjects: 66
Study: 3608343

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 07.00 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 13.00 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 19.00 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 01.00 hours
Number of subjects: 8
Study: 29579503

Group type: EXPERIMENTAL
Intervention: Daily PIVO blood collections
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine phlebotomy
Number of subjects: 160
Study: 27544678

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study: 26278513

Group type: EXPERIMENTAL
Intervention: Pre-filled pen (75 mg and 150 mg doses)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pre-filled syringe (75 mg and 150 mg doses)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pre-filled pen
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pre-filled syringe
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pre-filled pen and syringe
Number of subjects: 400
Study: 24016489

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 0
Study: 20026578

Group type: EXPERIMENTAL
Intervention: Maintenance integrated health care programme (n = 11)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (n = 16)
Number of subjects: 40
Study: 18173308

Group type: EXPERIMENTAL
Intervention: 3DAC MR imaging on a 3-tesla system
Number of subjects: 33
Study: 15738708

Group type: EXPERIMENTAL
Intervention: Modified Continuous Glucose Monitoring System (CGMS) sensor
Number of subjects: 200
Study: 12957251

Group type: EXPERIMENTAL
Intervention: RCT plus amifostine (300 mg/m² daily i.v. infusion)
Number of subjects: 73

Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 73
Study: 11235460

Group type: EXPERIMENTAL
Intervention: Warmed arthroscopic irrigation solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Room-temperature irrigation solution
Number of subjects: 24
Study: 8878577

Group type: COMPARATOR
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin (8 to 12 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roxithromycin (8 to 12 mg/kg)
Number of subjects: 12
Study: 1521653

Group type: EXPERIMENTAL
Intervention: Luteal phase leuprolide acetate (LA) initiated pituitary down regulation followed by human menopausal gonadotropins (hMG)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and human menopausal gonadotropins (hMG)
Number of subjects: 408
Study: 6380347

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg by mouth daily, increased to 1200 mg daily after one month)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 128
Study: 30612112

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2-3 times/week during 4 months + lifestyle management
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg, three times/day during 4 months + lifestyle management
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lifestyle management alone
Number of subjects: 123
Study: 30062577

Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, and 30 mg/70 kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (400 mg/70 kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26655430

Group type: EXPERIMENTAL
Intervention: Culturally targeted 12-week multimodal lifestyle intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 24206010

Group type: EXPERIMENTAL
Intervention: Cold therapy (cold pack applied over abdomen and back for 10 minutes every 30 minutes during first phase of labour; cold pack over perineum for 5 minutes every 15 minutes during second phase)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no cold therapy)
Number of subjects: 64
Study: 20337606

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab alone (BEVA group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab in combination with photodynamic therapy (COMB group)
Number of subjects: 41
Study: 19066436

Group type: EXPERIMENTAL
Intervention: Conjunctival suture removal 4 weeks postoperatively
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (suture remained in place)
Number of subjects: 69
Study: 17242095

Group type: EXPERIMENTAL
Intervention: Eritoran 2 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Eritoran 12 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Eritoran 28 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 16286586

Group type: EXPERIMENTAL
Intervention: TAXUS Moderate Release paclitaxel-eluting stent
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control (uncoated Express2 stent)
Number of subjects: 448
Study: 11929196

Group type: EXPERIMENTAL
Intervention: DHA (1.5g DHA/day for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (10 mixed plant oil capsules for 2 months)
Number of subjects: 40
Study: 10403065

Group type: EXPERIMENTAL
Intervention: Rizatriptan (5HT1B/1D receptor agonist)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual migraine therapy
Number of subjects: 164
Study: 7726322

Group type: EXPERIMENTAL
Intervention: Inositol (12 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2383198

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha‐isopropylester (PGF2 alpha‐IE) 0.5 microgram, twice daily for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7239398

Group type: EXPERIMENTAL
Intervention: Bromopride (Cascapride)
Number of subjects: 0
Study: 31830926

Group type: EXPERIMENTAL
Intervention: DAGIS intervention (22-week programme)
Number of subjects: 0
Study: 28027950

Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat diet
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Healthy Low-Carbohydrate diet
Number of subjects: 600
Study: 27978858

Group type: EXPERIMENTAL
Intervention: Online CBT-based stress management intervention with facilitated bulletin board
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Online CBT-based stress management intervention without facilitated bulletin board
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 90
Study: 24509270

Group type: EXPERIMENTAL
Intervention: Transcatheter intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 229
Study: 22992070

Group type: EXPERIMENTAL
Intervention: Intra Abdominal Balloon Occlusion (IABO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no IABO)
Number of subjects: 33
Study: 19887475

Group type: EXPERIMENTAL
Intervention: Vorinostat (800 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17848652

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 16390

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 16390
Study: 15044183

Group type: EXPERIMENTAL
Intervention: LoCO(2) (8 mmHg below resting values)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HiCO(2) (8 mmHg above resting values)
Number of subjects: 8
Study: 11433046

Group type: EXPERIMENTAL
Intervention: Educational outreach intervention for families and physicians, including 2 meetings with a physician peer leader and feedback on previous prescribing rates. Parents received a CDC brochure on antibiotic use.
Number of subjects: 14468

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 14468

Group type: EXPERIMENTAL
Intervention: Educational outreach intervention for families and physicians.
Number of subjects: 14468
Study: 9614724

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta-1b (Betaferon)
Number of subjects: 0
Study: 7996376

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1600 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 16
Study: 3054429

Group type: EXPERIMENTAL
Intervention: Glycerol-insulin treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard insulin treatment
Number of subjects: 8
Study: 4873660

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 31129983

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for nightmares delivered over 4 weeks in addition to treatment as usual (TAU)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for nightmares
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study: 29061270

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 351

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 351
Study: 25933201

Group type: EXPERIMENTAL
Intervention: Topical application of rhFGF-2/HA in the intrabony defect
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open debridement with papilla preservation flaps (Control)
Number of subjects: 30
Study: 23959815

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 267
Study: 21532516

Group type: COMPARATOR
Intervention: saline‐F
Number of subjects: 18

Group type: COMPARATOR
Intervention: CMC‐F
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEG‐F
Number of subjects: 18
Study: 18362510

Group type: EXPERIMENTAL
Intervention: Obese adult PWS subjects
Number of subjects: 21
Study: 16172169

Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing test in HOCM patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HNCM group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 22
Study: 12906341

Group type: EXPERIMENTAL
Intervention: Integration of mental health clinical nurse specialist (CNS) care
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control firm physicians notified prior to encounter
Number of subjects: 268
Study: 10789602

Group type: EXPERIMENTAL
Intervention: sustained-release nifedipine
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: temperature biofeedback
Number of subjects: 313

Group type: COMPARATOR
Intervention: control (electromyographic) biofeedback
Number of subjects: 313
Study: 9125101

Group type: EXPERIMENTAL
Intervention: Neutralizing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distracting
Number of subjects: 0
Study: 8450166

Group type: EXPERIMENTAL
Intervention: Clentiazem 40 mg/day
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clentiazem 80 mg/day
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Clentiazem 120 mg/day
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 3512795

Group type: EXPERIMENTAL
Intervention: Nizofenone
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 30337444

Group type: EXPERIMENTAL
Intervention: SAR156597 Q2W
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: SAR156597 QW
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 28351412

Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Number of subjects: 144

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 25938830

Group type: EXPERIMENTAL
Intervention: 3DCRT followed by TACE (Group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: TACE followed by 3DCRT (Group B)
Number of subjects: 65
Study: 23640005

Group type: EXPERIMENTAL
Intervention: Pelvic Toner Device (PTD) with PFMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard PFMT (ST)
Number of subjects: 40
Study: 19804443

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) allergen inhalation challenge
Number of subjects: 6

Group type: COMPARATOR
Intervention: Grass pollen (GP) allergen inhalation challenge
Number of subjects: 6
Study: 18583910

Group type: EXPERIMENTAL
Intervention: DermaSilk (with AEM 5772/5 antimicrobial finish)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unmodified silk (without AEM 5772/5 antimicrobial finish)
Number of subjects: 30
Study: 16902074

Group type: EXPERIMENTAL
Intervention: Subsidized, quality recreation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self‐financed recreation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsidized recreation
Number of subjects: 0
Study: 12777279

Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 32
Study: 11044239

Group type: EXPERIMENTAL
Intervention: Fistula presence
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Race (Black vs Non-Black)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Obesity (BMI)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1824
Study: 9323286

Group type: EXPERIMENTAL
Intervention: Single-dose prednisolone (2 mg/kg per day as a single morning dose for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Divided-dose prednisolone (2 mg/kg per day in three divided doses for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both groups (single-dose and divided-dose)
Number of subjects: 106
Study: 8203183

Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (5MI), n=23
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo, n=19
Number of subjects: 42
Study: 3910710

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 126
Study: 31391092

Group type: EXPERIMENTAL
Intervention: Yinang formulation (YNF) plus conventional therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus conventional therapy
Number of subjects: 72
Study: 28777672

Group type: EXPERIMENTAL
Intervention: Grounded khat leaves extract (45 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (juice only)
Number of subjects: 30
Study: 26952221

Group type: EXPERIMENTAL
Intervention: 0.1mg intrathecal morphine (Group I, n=22)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.4mg intrathecal morphine (Group II, n=26)
Number of subjects: 48
Study: 24254493

Group type: EXPERIMENTAL
Intervention: TENS at 150 pps
Number of subjects: 20

Group type: COMPARATOR
Intervention: TENS at 60 pps
Number of subjects: 20
Study: 21931327

Group type: EXPERIMENTAL
Intervention: Family-based behavioural treatment (FBBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 72